DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20164142

Characteristics, determinants and cost implications of severe adverse drug reactions in the intensive coronary care unit of a hospital

Nitin S. Kunnoor, Anand R. Kanaki, Sharanabasappa Singanal

Abstract


Background: The objective of the study was to determine the predictors, frequency, characteristics and incremental costs of severe Adverse Drug Reactions in the Intensive Coronary Care Unit (ICCU) of a hospital.

Methods: Two trained physicians prospectively reviewed case records of all in-patients admitted to ICCU over one year (July 2015 to June 2016) and identified ADRs. Each ADR was assessed for causality, severity, predictability and preventability. Determinants of severe ADRs were identified using multiple binary logistic regression analysis. Cost of severe ADR was estimated based on the corrected duration of excess hospital stay after adjusting for age, gender, co-morbid conditions and number of drugs.

Results: Of 573 cases admitted during one year, 47 (8%) patients had 56 severe ADRs. Streptokinase (16.1%) was the commonest drug associated with severe ADRs. Arrhythmias (30.4%) were the commonest severe ADR. Presence of arrhythmias (OR 4.54, 95% CI 2.25–9.14), renal dysfunction (OR 2.27, 95% CI 1.01–5.11) and poly-pharmacy (>10 drugs) (OR 1.13, 95% CI 1.007- 1.254) were found to be the predictors for occurrence of severe ADRs. Majority of severe ADRs were found to be probable 30 (53.6%). 46 (82%) were predictable and 25 (44.6%) probably preventable severe ADRs. Patients with severe ADRs had a longer duration of ICCU (0.8 extra day) and hospital stay (1.5 extra days) (adjusted analysis). The mean incremental cost incurred by patients in the severe ADR group was $ 32 (INR 2170/-) per patient based on the corrected duration of hospital stay.

Conclusions: Severe ADRs in ICCU add considerably to treatment costs. Cardiac arrhythmias, renal dysfunction, and polypharmacy are important predictors of severe ADRs.


Keywords


Cost, Intensive care, ICCU, Severe ADRs

Full Text:

PDF

References


Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-5.

Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-9.

Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41(2):192-9.

White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics. 1999;15(5):445-58.

Wester K, Jonsson AK, Spigset O, Druid H, Hagg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol. 2008;65(4):573-9.

Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol. 2007;7:8.

Mohebbi N, Shalviri G, Salarifar M, Salamzadeh J, Gholami K. Adverse drug reactions induced by cardiovascular drugs in cardiovascular care unit patients. Pharmacoepidemiol Drug Saf. 2010;19(9):889-94.

Lindquist M. The need for definitions in pharmacovigilance. Drug Saf. 2007;30(10):825-30.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229-32.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27(6):538.

Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol. 1998;45(3):301-8.

Hallas J, Harvald B, Gram LF, Grodum E, Brøsen K, Haghfelt T, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med. 1990;228:83-90.

Mohebbi N, Shalviri G, Salarifar M, Salamzadeh J, Gholami K. Adverse drug reactions induced by cardiovascular drugs in cardiovascular care unit patients. Pharmacoepidemiol Drug Saf. 2010;19(9):889-94.

Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol. 1998;45(3):301-8.

Gautier S, Bachelet H, Bordet R, Caron J. The cost of adverse drug reactions. Expert Opin Pharmacother. 2003;4(3):319-26.

Janaje Munasinghe TM, Singer DR. Costs and prevention of adverse drug reactions. Eur J Intern Med. 2001;12(5):403-5.

Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse drug reactions in hospitals: a narrative review. Curr Drug Saf. 2007;2(1):79-87.

Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004;57(2):121-6.

O'Brien TJ, Cascino GD, So EL, Hanna DR. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology. 1998;51(4):1034-9.

Aggarwal M, Khan IA. Hypertensive crisis: hypertensive emergencies and urgencies. Cardiol Clin. 2006;24(1):135-46.

Letchumanan P, Thumboo J. Danazol in the treatment of systemic lupus erythematosus: a qualitative systematic review. Semin Arthritis Rheum. 2011;40(4):298-306.

Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol. 1998;45(3):301-8.

Gersh BJ, Sliwa K, Mayosi BM, Yusuf S. Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. Eur Heart J. 2010;31(6):642-8.

Gautier S, Bachelet H, Bordet R, Caron J. The cost of adverse drug reactions. Expert Opin Pharmacother. 2003;4(3):319-26.